Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved cyclophosphamide in combination with doxorubicin, vincristine, and prednisolone (mini-CHOP Therapy) (21 days) for the treatment of non-hodgkin lymphoma (NHL) in patients aged greater than 80 or with significant co-morbidities. The therapy regimen further states that rituximab is to be included for the treatment of CD20 positive patients.
This is written in the approval document as:
Treatment of Non Hodgkin Lymphoma in patients aged greater than 80 or with significant co-morbidities. Rituximab to be included in all CD20 positive patients.
Citation
(R*)- miniCHOP Therapy - 21 days, 2023, version number 4, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD20 + | Non-Hodgkin Lymphoma | Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vinorelbine |